Literature DB >> 8422284

Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.

J Verweij1, K Krzemieniecki, T Kok, A Poveda, C van Pottelsberghe, M van Glabbeke, H Mouridsen.   

Abstract

The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas. No responses were seen in 18 evaluable patients. Toxicity consisted mainly of nausea/vomiting. It is concluded that oral miltefosine has no activity in soft tissue sarcoma.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8422284     DOI： 10.1016/0959-8049(93)90177-h

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  7 in total

Review 1.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma.

Authors:  Roberta Marino; Dana C Baiu; Saswati Bhattacharya; Benjamin Titz; Ellen Hebron; Bryan D Menapace; Sorabh Singhal; Jens C Eickhoff; Fotis Asimakopoulos; Jamey P Weichert; Mario Otto
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

3.  Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.

Authors:  I Fichtner; R Zeisig; H Naundorf; S Jungmann; D Arndt; G Asongwe; J A Double; M C Bibby
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.

Authors:  J M Terwogt; I A Mandjes; H Sindermann; J H Beijnen; W W ten Bokkel Huinink
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

Review 5.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).

Authors:  George Mihai Nitulescu; Denisa Margina; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Emmanouil Saloustros; Concettina Fenga; Demetrios Α Spandidos; Massimo Libra; Aristidis M Tsatsakis
Journal:  Int J Oncol       Date:  2015-12-24       Impact factor: 5.650

Review 6.  The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.

Authors:  Joyce Pijpers; Margriet L den Boer; Dirk R Essink; Koert Ritmeijer
Journal:  PLoS Negl Trop Dis       Date:  2019-02-11

7.  Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.

Authors:  M Lohmeyer; P Workman
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.